Free tool
FAERS Monitor: Tysabri
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125104 or its brand name (Tysabri, Natalizumab). Reports on generic versions are filed under their own applications.
Reports
181,255
Serious
56,644
31% of reports
Hospitalization
34,723
Death reported
5,131
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue19,632
- multiple sclerosis relapse16,953
- headache10,010
- multiple sclerosis9,821
- gait disturbance9,507
- fall8,050
- asthenia8,012
- memory impairment7,972
- malaise7,449
- drug ineffective6,917
- urinary tract infection6,323
- pain5,988
- balance disorder5,695
- hypoaesthesia5,437
- pain in extremity4,942
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 1,355 |
| 2006 | 48 |
| 2007 | 559 |
| 2008 | 1,549 |
| 2009 | 2,555 |
| 2010 | 20,069 |
| 2011 | 25,662 |
| 2012 | 22,980 |
| 2013 | 29,497 |
| 2014 | 12,502 |
| 2015 | 7,069 |
| 2016 | 8,948 |
| 2017 | 8,570 |
| 2018 | 8,295 |
| 2019 | 6,205 |
| 2020 | 5,145 |
| 2021 | 3,964 |
| 2022 | 4,362 |
| 2023 | 3,971 |
| 2024 | 3,274 |
| 2025 | 2,831 |
| 2026 | 1,843 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,872,904 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| multiple sclerosis relapseSignal | 16,953 | 37.8 | 37.2 | 458,695 |
| multiple sclerosisSignal | 9,821 | 29.7 | 29.1 | 217,179 |
| balance disorderSignal | 5,695 | 8.1 | 7.9 | 33,311 |
| memory impairmentSignal | 7,972 | 7.1 | 6.9 | 39,509 |
| gait disturbanceSignal | 9,507 | 6.0 | 5.9 | 38,098 |
| urinary tract infectionSignal | 6,323 | 4.4 | 4.3 | 16,290 |
| hypoaesthesiaSignal | 5,437 | 4.3 | 4.2 | 13,542 |
| fatigueSignal | 19,632 | 3.0 | 2.9 | 26,069 |
| fallSignal | 8,050 | 2.9 | 2.8 | 9,593 |
| astheniaSignal | 8,012 | 2.5 | 2.5 | 7,215 |
| malaise | 7,449 | 2.0 | 1.9 | 3,669 |
| pain in extremity | 4,942 | 2.0 | 1.9 | 2,325 |
| headache | 10,010 | 1.9 | 1.8 | 4,083 |
| pain | 5,988 | 1.1 | 1.1 | 95 |
| drug ineffective | 6,917 | 0.6 | 0.6 | 1,868 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.